Ventures West 6

Epic Games is an American video game and software company that develops games for PC, consoles, mobile devices, augmented reality, virtual reality, and the Web. It licenses and provides its Unreal Engine technology to other developers, enabling the creation of high-fidelity, interactive experiences. The company operates a digital storefront that allows developers to publish, distribute, and monetize games and 3D content, supporting cross-platform compatibility and scalable performance across PC, console, mobile, and immersive devices.

Aquinox Pharmaceuticals Inc., based in Vancouver, Canada, is a clinical-stage pharmaceutical company focused on discovering and developing oral drug candidates for the treatment of inflammatory diseases and cancer. Founded in 2004, the company is engaged in the development and commercialization of small molecule therapeutics. Its notable offerings include AQX-MN100, a drug targeting both cancer and inflammatory conditions, alongside a program aimed at SH2-containing inositol 5'-phosphatase inhibition for blood cell recovery. As of July 2020, Aquinox Pharmaceuticals operates as a subsidiary of Taro Pharmaceuticals Inc.

Spectra7 Microsystems Inc. is an analog semiconductor company based in San Jose, California, with operations in Canada and China. It specializes in providing high-performance solutions that deliver exceptional bandwidth, speed, and resolution, catering to the needs of leading consumer electronics manufacturers. The company's product offerings include virtual reality components, such as the VR7050, which facilitates lightweight and ultra-thin interconnects for gesture recognition and motion control. Additionally, it produces augmented reality solutions, including the AR-Connect integrated cable and chipset line, designed for AR vision systems and wearable devices. Spectra7 also develops high-bandwidth interconnects for data centers and provides USB 3.1 solutions for ultra-thin laptops, tablets, and mobile devices. Its innovations are aimed at enhancing connectivity across various markets, including virtual reality, augmented reality, and industrial design.

Alder BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Bothell, Washington, focused on discovering, developing, and commercializing therapeutic antibodies. The company aims to transform treatment paradigms for patients with migraine and other conditions, utilizing proprietary technologies to enhance the efficacy and durability of therapeutic responses. Its lead product candidate, eptinezumab, is a monoclonal antibody designed to prevent migraines, currently in late-stage clinical development. Additionally, Alder is developing ALD1910, a preclinical monoclonal antibody for migraine prevention, and Clazakizumab, which targets interleukin-6 and has completed two Phase 2b clinical trials. Alder also collaborates with CSL Limited to develop Clazakizumab for preventing solid organ transplant rejection. The company operates primarily in the United States, Australia, and Ireland, where it seeks to address unmet medical needs in various therapeutic areas, including cancer, autoimmune diseases, and inflammatory disorders. Founded in 2002, Alder BioPharmaceuticals operates as a subsidiary of H. Lundbeck A/S.

NeurAxon, Inc. is a Canadian company focused on discovering and developing therapeutics for pain management by targeting neuronal nitric oxide synthase. Founded in 2004 and headquartered in Toronto, NeurAxon is advancing a pipeline of oral products aimed at treating various pain conditions, including acute migraine, neuropathic pain, chronic daily headache, inflammatory pain, migraine prophylaxis, and severe pain. By utilizing selective inhibitors of nitric oxide synthase, the company seeks to provide effective solutions for individuals suffering from these conditions.

Celator Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for cancer treatment. Utilizing its proprietary CombiPlex technology platform, the company designs and evaluates optimized drug combinations that integrate traditional chemotherapies with molecularly targeted agents to enhance anti-cancer efficacy. Notable products in its pipeline include VYXEOS, a nano-scale liposomal formulation of irinotecan and floxuridine, and CPX-351, a liposomal formulation of cytarabine and daunorubicin, both in Phase III clinical trials for acute myeloid leukemia. Additionally, CPX-1, a liposomal formulation of irinotecan and floxuridine, has completed Phase II studies for colorectal cancer. Celator also has a preclinical candidate, CPX-8, which is a hydrophobic docetaxel prodrug nanoparticle formulation. Founded in 1999 and headquartered in Ewing, New Jersey, Celator Pharmaceuticals operates as a subsidiary of Jazz Pharmaceuticals Public Limited Company.

Aquinox Pharmaceuticals Inc., based in Vancouver, Canada, is a clinical-stage pharmaceutical company focused on discovering and developing oral drug candidates for the treatment of inflammatory diseases and cancer. Founded in 2004, the company is engaged in the development and commercialization of small molecule therapeutics. Its notable offerings include AQX-MN100, a drug targeting both cancer and inflammatory conditions, alongside a program aimed at SH2-containing inositol 5'-phosphatase inhibition for blood cell recovery. As of July 2020, Aquinox Pharmaceuticals operates as a subsidiary of Taro Pharmaceuticals Inc.

SWITCH Materials Inc. is a Canadian company founded in 2007, specializing in advanced materials that enable innovative smart window solutions for automotive applications, particularly for OEMs and Tier 1 suppliers. The company focuses on developing proprietary organic molecules that can switch optical properties on command, allowing for functionalities such as automatic darkening of sunroofs in sunlight to reduce heat and glare. Their technology integrates seamlessly into various applications, including automotive glass, architectural glass, and eyewear. SWITCH Materials also conducts extensive research and development in its laboratories and at Simon Fraser University’s 4D LABS, leveraging the expertise of materials scientists skilled in synthetic chemistry, polymer processing, and optics. The company aims to contribute to lower emissions and enhanced customer experiences in electric vehicle markets, as well as in custom solar management applications.

Fresco Microchip is a fabless semiconductor company specializing in the development of integrated circuits that address the conversion of analog to digital signals. Targeting the consumer electronics market, the company integrates three core technologies: next-generation radio frequency (RF), mixed-signal, and digital signal processing (DSP). Fresco Microchip employs its proprietary Agile Signal Processing technology to achieve universal legacy demodulation using low-cost CMOS, enabling television-quality video output without the inconsistencies associated with traditional analog methods. By combining digital demodulation with its patented iSAW technology and agileSP, Fresco Microchip offers a comprehensive hybrid solution that enhances video quality while maintaining cost efficiency.

QuickPlay Media Inc. is a prominent provider of cloud-based managed service solutions for the distribution of media to IP-connected devices. Founded in 2004 and headquartered in Toronto, Canada, the company specializes in delivering over-the-top (OTT) video services, enabling clients to deploy content across both managed IPTV set-top boxes and unmanaged devices. QuickPlay's OpenVideo platform offers robust capabilities for live streaming, video on demand, and monetization strategies such as dynamic advertisement insertion and personalized content. Additionally, the company supports pay TV services, allowing traditional cable operators to transition to multiscreen solutions across various networks. With facilities in major cities including San Diego, Singapore, Chennai, and Frankfurt, QuickPlay serves a global clientele, including some of the largest communications and media companies.

Zeugma Systems is a privately held telecommunications equipment supplier focused on providing open solutions that enhance service deployment for broadband service providers. The company's flagship product, the Zeugma Services Node, is a service delivery router that combines extensive computing power with advanced service and subscriber management capabilities in a fully redundant system. This innovative equipment allows service providers to quickly prototype and launch new revenue-generating services, manage and monitor session flows on a granular level, and enforce quality of service policies. Additionally, Zeugma Systems offers Zeugma OSS for configuration and health management, along with Smart Series Applications that include tools for quality of experience monitoring, enhanced Internet-based video services, improved voice over IP services, and customizable billing frameworks. Overall, Zeugma Systems aims to streamline the delivery of high-value services while reducing the complexity and number of edge devices required in broadband networks.

MacroGenics, Inc. is a biopharmaceutical company based in Rockville, Maryland, specializing in the discovery and development of antibody-based therapeutics for cancer treatment. Founded in 2000, the company focuses on immuno-oncology and has a diverse pipeline of product candidates. Key developments include Margetuximab, a monoclonal antibody in Phase III clinical trials targeting HER2-expressing tumors, and Flotetuzumab, a DART molecule aimed at treating acute myeloid leukemia. Other investigational products include MGA012, MGD013, MGD019, and Enoblituzumab, which target various immune checkpoints and tumor-associated antigens. MacroGenics is also advancing combination therapies and antibody-drug conjugates, such as MGC018, which targets solid tumors expressing B7-H3. The company has formed strategic collaborations with notable partners, enhancing its research and development efforts in the biopharmaceutical landscape.

Celator Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for cancer treatment. Utilizing its proprietary CombiPlex technology platform, the company designs and evaluates optimized drug combinations that integrate traditional chemotherapies with molecularly targeted agents to enhance anti-cancer efficacy. Notable products in its pipeline include VYXEOS, a nano-scale liposomal formulation of irinotecan and floxuridine, and CPX-351, a liposomal formulation of cytarabine and daunorubicin, both in Phase III clinical trials for acute myeloid leukemia. Additionally, CPX-1, a liposomal formulation of irinotecan and floxuridine, has completed Phase II studies for colorectal cancer. Celator also has a preclinical candidate, CPX-8, which is a hydrophobic docetaxel prodrug nanoparticle formulation. Founded in 1999 and headquartered in Ewing, New Jersey, Celator Pharmaceuticals operates as a subsidiary of Jazz Pharmaceuticals Public Limited Company.

Fresco Microchip is a fabless semiconductor company specializing in the development of integrated circuits that address the conversion of analog to digital signals. Targeting the consumer electronics market, the company integrates three core technologies: next-generation radio frequency (RF), mixed-signal, and digital signal processing (DSP). Fresco Microchip employs its proprietary Agile Signal Processing technology to achieve universal legacy demodulation using low-cost CMOS, enabling television-quality video output without the inconsistencies associated with traditional analog methods. By combining digital demodulation with its patented iSAW technology and agileSP, Fresco Microchip offers a comprehensive hybrid solution that enhances video quality while maintaining cost efficiency.

BelAir Networks specializes in the development of advanced wireless networking equipment designed to support high-performance wireless networks for service providers. Established in 2002, the company offers a range of products including indoor access points, outdoor picocell base stations, and comprehensive control and management systems. These solutions enable leading telecommunications companies, such as AT&T and Comcast, to deploy scalable and flexible wireless networks that meet the demands of increasing mobile data usage. BelAir Networks is recognized for its patented switched mesh architecture, which facilitates the creation of reliable wireless access and backhaul networks. Additionally, the company provides software solutions that utilize GIS-based mapping and GPS technology to streamline the setup and management of various Wi-Fi networks. With a focus on enhancing revenue and competitiveness for its customers, BelAir Networks has established a strong presence among Tier 1 carriers and government clients.

Viigo is a developer of a content mobilization platform that provides a range of modules designed to enhance user engagement with real-time information. The platform includes a News and RSS module for accessing news, insights, and blogs; a Weather module for viewing current temperatures and forecasts globally; a Sports module that delivers live event updates, schedules, and results; and a Business and Finance module that allows users to create and manage their own stock portfolios, calculate exchange rates, and oversee their online accounts. Since 2012, Viigo has also supported small business start-ups by offering multiple grants each year, fostering innovation and entrepreneurship within the community.

Zeugma Systems is a privately held telecommunications equipment supplier focused on providing open solutions that enhance service deployment for broadband service providers. The company's flagship product, the Zeugma Services Node, is a service delivery router that combines extensive computing power with advanced service and subscriber management capabilities in a fully redundant system. This innovative equipment allows service providers to quickly prototype and launch new revenue-generating services, manage and monitor session flows on a granular level, and enforce quality of service policies. Additionally, Zeugma Systems offers Zeugma OSS for configuration and health management, along with Smart Series Applications that include tools for quality of experience monitoring, enhanced Internet-based video services, improved voice over IP services, and customizable billing frameworks. Overall, Zeugma Systems aims to streamline the delivery of high-value services while reducing the complexity and number of edge devices required in broadband networks.

Sixtron Enterprises Inc. specializes in the development of anti-reflective coating solutions for the solar cell industry, with a particular focus on c-Si solar cell production lines. The company's flagship product, SunBox, is a gas handling solution designed to enhance the efficiency of solar cell manufacturing. In addition to its work in the solar sector, Sixtron is advancing thin film coating solutions applicable to the electronics and industrial coatings industries. These thin films are notable for their unique optical and mechanical properties and can be deposited without the complex requirements associated with hazardous silane gas. Founded in 2004 and based in Calgary, Canada, Sixtron Enterprises Inc. was previously known as SiXtron Advanced Materials Inc.

QuickPlay Media Inc. is a prominent provider of cloud-based managed service solutions for the distribution of media to IP-connected devices. Founded in 2004 and headquartered in Toronto, Canada, the company specializes in delivering over-the-top (OTT) video services, enabling clients to deploy content across both managed IPTV set-top boxes and unmanaged devices. QuickPlay's OpenVideo platform offers robust capabilities for live streaming, video on demand, and monetization strategies such as dynamic advertisement insertion and personalized content. Additionally, the company supports pay TV services, allowing traditional cable operators to transition to multiscreen solutions across various networks. With facilities in major cities including San Diego, Singapore, Chennai, and Frankfurt, QuickPlay serves a global clientele, including some of the largest communications and media companies.

Presidio Pharmaceuticals, Inc. is a specialty pharmaceutical company based in San Francisco, California, focused on the discovery and development of small-molecule antiviral therapeutics for viral infections, particularly hepatitis C virus (HCV) and HIV. Founded in 2006, the company is dedicated to creating innovative therapies, including pan-genotypic HCV NS5A inhibitors and ravidasvir hydrochloride, which target specific proteins of the HCV. Presidio's antiviral therapeutics are designed for daily oral dosing and can be used in combination with other antiviral treatments to enhance efficacy and combat viral resistance. Through its efforts, Presidio aims to provide effective drug therapies to patients dealing with various strains of hepatitis.

NeurAxon, Inc. is a Canadian company focused on discovering and developing therapeutics for pain management by targeting neuronal nitric oxide synthase. Founded in 2004 and headquartered in Toronto, NeurAxon is advancing a pipeline of oral products aimed at treating various pain conditions, including acute migraine, neuropathic pain, chronic daily headache, inflammatory pain, migraine prophylaxis, and severe pain. By utilizing selective inhibitors of nitric oxide synthase, the company seeks to provide effective solutions for individuals suffering from these conditions.

Celator Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for cancer treatment. Utilizing its proprietary CombiPlex technology platform, the company designs and evaluates optimized drug combinations that integrate traditional chemotherapies with molecularly targeted agents to enhance anti-cancer efficacy. Notable products in its pipeline include VYXEOS, a nano-scale liposomal formulation of irinotecan and floxuridine, and CPX-351, a liposomal formulation of cytarabine and daunorubicin, both in Phase III clinical trials for acute myeloid leukemia. Additionally, CPX-1, a liposomal formulation of irinotecan and floxuridine, has completed Phase II studies for colorectal cancer. Celator also has a preclinical candidate, CPX-8, which is a hydrophobic docetaxel prodrug nanoparticle formulation. Founded in 1999 and headquartered in Ewing, New Jersey, Celator Pharmaceuticals operates as a subsidiary of Jazz Pharmaceuticals Public Limited Company.

6N Silicon, Inc. is a manufacturer of solar grade silicon and polysilicon, primarily serving the solar cell production industry across North America, Europe, and Asia. Founded in 2006 and based in Vaughan, Canada, the company has developed an innovative low-temperature process that utilizes aluminum as a metal solvent to purify metallurgical grade silicon into high purity solar grade silicon. This unique purification method enhances the efficiency and quality of silicon for the photovoltaic sector. 6N Silicon operates as a wholly owned subsidiary of CaliSolar, Inc., focusing on advancing sustainable energy solutions through its specialized silicon production processes.

Aquinox Pharmaceuticals Inc., based in Vancouver, Canada, is a clinical-stage pharmaceutical company focused on discovering and developing oral drug candidates for the treatment of inflammatory diseases and cancer. Founded in 2004, the company is engaged in the development and commercialization of small molecule therapeutics. Its notable offerings include AQX-MN100, a drug targeting both cancer and inflammatory conditions, alongside a program aimed at SH2-containing inositol 5'-phosphatase inhibition for blood cell recovery. As of July 2020, Aquinox Pharmaceuticals operates as a subsidiary of Taro Pharmaceuticals Inc.

Like most other players in this space, EQO helps save you money on long distance calls by bridging long distance calls over cheaper IP lines. What essentially happens is that your phone an EQO server on a local number, which transfers your call onto cheaper data lines across the internet, and then hops back onto standard phone lines and through another local number to the callee. The call only costs you minutes from your phone plan and the data cost for the VOIP line which runs 95-98% less than standard calling rates. Callers will store value for phone calls in EQO credits. However, calling another EQO user is free.

RapidMind, Inc. is a software development company based in Waterloo, Canada, that specializes in providing a platform for software vendors to optimize performance on multi-core and stream processors, including GPUs. Founded in 2004 as Serious Hack, Inc. and rebranded in 2006, the company offers the RapidMind Multi-core Development Platform, which helps software organizations reduce risk and lower development costs while enabling single-threaded applications to fully utilize multi-core processors. In 2009, RapidMind's team and products were acquired by Intel Corporation, where they continued to develop similar technologies under the "Ct Technology" project.

Serveron Corporation specializes in developing and supporting online transformer products and diagnostic services. The company provides transformer monitors that deliver essential asset data, including dissolved gas analysis of insulating oil in power transformers and other oil-filled equipment. Its offerings also include monitoring services that allow users to access data from any internet-connected Windows PC, transformer bushing monitors for power factor testing, and advisory services to help utilities manage their transformer fleets. Additionally, Serveron focuses on energy asset management, enabling real-time monitoring, control, and reporting of remote energy systems. The company serves utilities, industrial users, and service organizations both in the United States and internationally. Headquartered in Hillsboro, Oregon, Serveron Corporation operates as a subsidiary of BPL Global, Ltd.

Osprey Pharmaceuticals USA, Inc., established in 2008 and headquartered in San Francisco, specializes in developing protein therapeutics to treat inflammatory and immune diseases. Its primary focus is on advancing a pipeline of proprietary fusion proteins called Leukocyte Population Modulators (LPMs), designed to selectively target and neutralize chemokine-activated leukocytes involved in various inflammatory conditions. The company's lead candidate, CCL2-LPM, targeting the CCR2 chemokine receptor, is currently in Phase Ib clinical trials for treating IgA nephropathy, an inflammatory kidney disease.

BelAir Networks specializes in the development of advanced wireless networking equipment designed to support high-performance wireless networks for service providers. Established in 2002, the company offers a range of products including indoor access points, outdoor picocell base stations, and comprehensive control and management systems. These solutions enable leading telecommunications companies, such as AT&T and Comcast, to deploy scalable and flexible wireless networks that meet the demands of increasing mobile data usage. BelAir Networks is recognized for its patented switched mesh architecture, which facilitates the creation of reliable wireless access and backhaul networks. Additionally, the company provides software solutions that utilize GIS-based mapping and GPS technology to streamline the setup and management of various Wi-Fi networks. With a focus on enhancing revenue and competitiveness for its customers, BelAir Networks has established a strong presence among Tier 1 carriers and government clients.

Alder BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Bothell, Washington, focused on discovering, developing, and commercializing therapeutic antibodies. The company aims to transform treatment paradigms for patients with migraine and other conditions, utilizing proprietary technologies to enhance the efficacy and durability of therapeutic responses. Its lead product candidate, eptinezumab, is a monoclonal antibody designed to prevent migraines, currently in late-stage clinical development. Additionally, Alder is developing ALD1910, a preclinical monoclonal antibody for migraine prevention, and Clazakizumab, which targets interleukin-6 and has completed two Phase 2b clinical trials. Alder also collaborates with CSL Limited to develop Clazakizumab for preventing solid organ transplant rejection. The company operates primarily in the United States, Australia, and Ireland, where it seeks to address unmet medical needs in various therapeutic areas, including cancer, autoimmune diseases, and inflammatory disorders. Founded in 2002, Alder BioPharmaceuticals operates as a subsidiary of H. Lundbeck A/S.

DabbleDB lets users build multiple database applications from a single database or spreadsheet. All users have to do is create a single database on DabbleDB and they can create multiple database applications like charts, maps and calendars. The product helps to leverage a single data source to do more work for you.

Zeugma Systems is a privately held telecommunications equipment supplier focused on providing open solutions that enhance service deployment for broadband service providers. The company's flagship product, the Zeugma Services Node, is a service delivery router that combines extensive computing power with advanced service and subscriber management capabilities in a fully redundant system. This innovative equipment allows service providers to quickly prototype and launch new revenue-generating services, manage and monitor session flows on a granular level, and enforce quality of service policies. Additionally, Zeugma Systems offers Zeugma OSS for configuration and health management, along with Smart Series Applications that include tools for quality of experience monitoring, enhanced Internet-based video services, improved voice over IP services, and customizable billing frameworks. Overall, Zeugma Systems aims to streamline the delivery of high-value services while reducing the complexity and number of edge devices required in broadband networks.

MacroGenics, Inc. is a biopharmaceutical company based in Rockville, Maryland, specializing in the discovery and development of antibody-based therapeutics for cancer treatment. Founded in 2000, the company focuses on immuno-oncology and has a diverse pipeline of product candidates. Key developments include Margetuximab, a monoclonal antibody in Phase III clinical trials targeting HER2-expressing tumors, and Flotetuzumab, a DART molecule aimed at treating acute myeloid leukemia. Other investigational products include MGA012, MGD013, MGD019, and Enoblituzumab, which target various immune checkpoints and tumor-associated antigens. MacroGenics is also advancing combination therapies and antibody-drug conjugates, such as MGC018, which targets solid tumors expressing B7-H3. The company has formed strategic collaborations with notable partners, enhancing its research and development efforts in the biopharmaceutical landscape.

Marqui is a cloud-based platform designed to empower marketing teams in the creation and management of website content. It offers an intuitive interface that allows users to produce and publish web-ready HTML, CSS, and JavaScript content without requiring coding skills. This enables team members to update their websites anytime and from any location, providing complete control over content creation, scheduling, and publication. In addition to its user-friendly platform, Marqui offers in-house services to assist with website and campaign design and development. The company also features a Client Success Team that provides live support, ensuring that users receive prompt assistance and that daily operations run smoothly.

Serveron Corporation specializes in developing and supporting online transformer products and diagnostic services. The company provides transformer monitors that deliver essential asset data, including dissolved gas analysis of insulating oil in power transformers and other oil-filled equipment. Its offerings also include monitoring services that allow users to access data from any internet-connected Windows PC, transformer bushing monitors for power factor testing, and advisory services to help utilities manage their transformer fleets. Additionally, Serveron focuses on energy asset management, enabling real-time monitoring, control, and reporting of remote energy systems. The company serves utilities, industrial users, and service organizations both in the United States and internationally. Headquartered in Hillsboro, Oregon, Serveron Corporation operates as a subsidiary of BPL Global, Ltd.

Avokia, Inc. provides database middleware software for enterprises and customers that enables the continuous availability of database information. It offers apLive, a database and operating system, which allows database clustering by supporting transaction replication in multiple horizontally scaled databases. The company offers its products for enterprise applications for disaster recovery at the database level. Avokia, Inc. was founded in 2000 and is headquartered in Toronto, Canada.

QuIC Financial Technologies, Inc. specializes in developing advanced simulation, risk calculation, and pricing platform solutions tailored for financial institutions and companies. The company offers a comprehensive product suite that includes the QuIC Engine, a high-performance desktop calculator capable of supercomputer-level processing, and QuIC Script, a vector computing language designed for formulating financial solutions. Additionally, QuIC Analytics delivers a range of analytical tools for various financial instruments, including derivatives, equities, and structured products. The company also provides QuIC Workbench for the customization and visualization of QuIC Script, along with integration products like QuIC Dispatch and QuIC Bridge to enhance interoperability with client systems. QuIC Financial Technologies further extends its services through product support, system integration, custom development, and consulting, addressing various risk management needs including market and credit risk. Founded in 1998 and headquartered in Vancouver, Canada, QuIC also maintains offices in London and New York.

Like most other players in this space, EQO helps save you money on long distance calls by bridging long distance calls over cheaper IP lines. What essentially happens is that your phone an EQO server on a local number, which transfers your call onto cheaper data lines across the internet, and then hops back onto standard phone lines and through another local number to the callee. The call only costs you minutes from your phone plan and the data cost for the VOIP line which runs 95-98% less than standard calling rates. Callers will store value for phone calls in EQO credits. However, calling another EQO user is free.

Resonant Medical is a Montreal-based company focused on developing, manufacturing, and commercializing 3D ultrasound image-guided adaptive radiotherapy products for cancer treatment. Founded in 2000, the company offers innovative solutions such as the Clarity Breast System for precise guidance in breast treatments, the Clarity Prostate System for non-invasive prostate treatments, and the Multi-Anatomy System for soft tissue anatomy guidance in various applications. These products are designed to enhance radiation therapy planning, verification, and delivery, providing a non-invasive and radiation-free approach that meets the technical and clinical needs of healthcare providers. Resonant Medical serves a range of professionals within cancer treatment centers, including physicians, physicists, therapists, and administrators. In 2010, the company was acquired by Elekta, further solidifying its commitment to advancing patient care in radiation therapy.

Fortiva provides an on-demand email archiving solution that addresses three key challenges – email storage management, legal discovery and regulatory compliance – without the headaches of managing an archive in-house. As a Software as a Service (SaaS) solution, the Fortiva Archiving Suite™ can be up and running in days, with minimal upfront capital costs and planning requirements.

Fresco Microchip is a fabless semiconductor company specializing in the development of integrated circuits that address the conversion of analog to digital signals. Targeting the consumer electronics market, the company integrates three core technologies: next-generation radio frequency (RF), mixed-signal, and digital signal processing (DSP). Fresco Microchip employs its proprietary Agile Signal Processing technology to achieve universal legacy demodulation using low-cost CMOS, enabling television-quality video output without the inconsistencies associated with traditional analog methods. By combining digital demodulation with its patented iSAW technology and agileSP, Fresco Microchip offers a comprehensive hybrid solution that enhances video quality while maintaining cost efficiency.

Alder BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Bothell, Washington, focused on discovering, developing, and commercializing therapeutic antibodies. The company aims to transform treatment paradigms for patients with migraine and other conditions, utilizing proprietary technologies to enhance the efficacy and durability of therapeutic responses. Its lead product candidate, eptinezumab, is a monoclonal antibody designed to prevent migraines, currently in late-stage clinical development. Additionally, Alder is developing ALD1910, a preclinical monoclonal antibody for migraine prevention, and Clazakizumab, which targets interleukin-6 and has completed two Phase 2b clinical trials. Alder also collaborates with CSL Limited to develop Clazakizumab for preventing solid organ transplant rejection. The company operates primarily in the United States, Australia, and Ireland, where it seeks to address unmet medical needs in various therapeutic areas, including cancer, autoimmune diseases, and inflammatory disorders. Founded in 2002, Alder BioPharmaceuticals operates as a subsidiary of H. Lundbeck A/S.

Celator Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for cancer treatment. Utilizing its proprietary CombiPlex technology platform, the company designs and evaluates optimized drug combinations that integrate traditional chemotherapies with molecularly targeted agents to enhance anti-cancer efficacy. Notable products in its pipeline include VYXEOS, a nano-scale liposomal formulation of irinotecan and floxuridine, and CPX-351, a liposomal formulation of cytarabine and daunorubicin, both in Phase III clinical trials for acute myeloid leukemia. Additionally, CPX-1, a liposomal formulation of irinotecan and floxuridine, has completed Phase II studies for colorectal cancer. Celator also has a preclinical candidate, CPX-8, which is a hydrophobic docetaxel prodrug nanoparticle formulation. Founded in 1999 and headquartered in Ewing, New Jersey, Celator Pharmaceuticals operates as a subsidiary of Jazz Pharmaceuticals Public Limited Company.

TimeSpring has developed a better way to protect data. With TimeSpring protecting your data is simple and automatic; data is always available and instantly recoverable. TimeSpring believes that businesses prefer to focus on their core expertise and their clients, not on the next backup. To accomplish this, TimeSpring gives computers an everlasting memory to ensure data is 100% available, infinitely preserved, and never overwritten.

NeurAxon, Inc. is a Canadian company focused on discovering and developing therapeutics for pain management by targeting neuronal nitric oxide synthase. Founded in 2004 and headquartered in Toronto, NeurAxon is advancing a pipeline of oral products aimed at treating various pain conditions, including acute migraine, neuropathic pain, chronic daily headache, inflammatory pain, migraine prophylaxis, and severe pain. By utilizing selective inhibitors of nitric oxide synthase, the company seeks to provide effective solutions for individuals suffering from these conditions.

PolyFuel, Inc. is a company that specializes in the design, development, engineering, and manufacturing of portable fuel cells aimed at powering electronic devices. Founded in 1999 and based in Mountain View, California, PolyFuel focuses on creating advanced membranes and systems to address the power limitations faced by portable electronics. Through its innovative approach, the company seeks to enhance the performance and efficiency of fuel cell technology, contributing to the advancement of energy solutions for various electronic applications.

Serveron Corporation specializes in developing and supporting online transformer products and diagnostic services. The company provides transformer monitors that deliver essential asset data, including dissolved gas analysis of insulating oil in power transformers and other oil-filled equipment. Its offerings also include monitoring services that allow users to access data from any internet-connected Windows PC, transformer bushing monitors for power factor testing, and advisory services to help utilities manage their transformer fleets. Additionally, Serveron focuses on energy asset management, enabling real-time monitoring, control, and reporting of remote energy systems. The company serves utilities, industrial users, and service organizations both in the United States and internationally. Headquartered in Hillsboro, Oregon, Serveron Corporation operates as a subsidiary of BPL Global, Ltd.

OncoGenex is a biotechnology company dedicated to addressing treatment resistance in cancer therapy by developing and commercializing innovative treatments. The company focuses on creating first-in-class therapies that aim to improve patient outcomes across various types of cancer. By leveraging advanced research and development, OncoGenex seeks to provide solutions that may redefine the standards of care in oncology, ultimately enhancing the effectiveness of cancer treatments for patients facing difficult challenges in their health journeys.

Photonics Control delivers sophisticated, intelligent and cost-effective solutions across a whole range of optical devices.

Serveron Corporation specializes in developing and supporting online transformer products and diagnostic services. The company provides transformer monitors that deliver essential asset data, including dissolved gas analysis of insulating oil in power transformers and other oil-filled equipment. Its offerings also include monitoring services that allow users to access data from any internet-connected Windows PC, transformer bushing monitors for power factor testing, and advisory services to help utilities manage their transformer fleets. Additionally, Serveron focuses on energy asset management, enabling real-time monitoring, control, and reporting of remote energy systems. The company serves utilities, industrial users, and service organizations both in the United States and internationally. Headquartered in Hillsboro, Oregon, Serveron Corporation operates as a subsidiary of BPL Global, Ltd.

SiberCore Technologies Incorporated is a pure-play, Internet IC company developing high-value-added Application Specific Standard Products (ASSPs) for intelligent hardware-based switching and routing platforms, such as Gigabit / Terabit Routers and Layer 2 / 3 / 4 Ethernet Switches. The company's initial products are a family of high-speed high-capacity packet forwarding engines based on Content Addressable Memories (CAM technology) which overcome the performance bottleneck associated with the network's routing table look-up function. This emerging market has been created by the demands of the explosion in datacom traffic, coupled with the worldwide deployment of fiber optics and DWDM. These broadband deployments have shifted the bottleneck from the Access and Transport section of the network, to the Routers and Switches connecting to these pipes. The company's founding technical team gained industry-wide recognition for its world-class design expertise in this area at Nortel Networks. A veteran Executive team in all the functional divisions of the company supplements this preeminent technical team.

PolyFuel, Inc. is a company that specializes in the design, development, engineering, and manufacturing of portable fuel cells aimed at powering electronic devices. Founded in 1999 and based in Mountain View, California, PolyFuel focuses on creating advanced membranes and systems to address the power limitations faced by portable electronics. Through its innovative approach, the company seeks to enhance the performance and efficiency of fuel cell technology, contributing to the advancement of energy solutions for various electronic applications.

Angstrom Power Incorporated researches and develops portable fuel cell devices. It provides Micro Hydrogen, an electrochemical energy converter that produces electricity, water vapor, and heat from hydrogen and airborne oxygen.

Interomex Biopharmaceuticals Inc. is dedicated to the identification of novel biological targets in key cellular processes with the aim of discovering lead compounds for the treatment of disease. The company’s proprietary Repressed Trans-activator (RTATM) technology can be used to detect protein-protein interactions between a host and an infectious agent, as well as within cells in normal and diseased states. A particular advantage of RTATM is its ability to detect the interactions of transcription transactivator proteins, which are key control points in viral infections and cell activation.

Convera is a prominent provider of payment services that specializes in facilitating business-to-business foreign exchange and cross-border payments across various sectors, including education, finance, travel, and healthcare. The company offers a comprehensive payments platform designed to help businesses manage international transactions efficiently and effectively. With a focus on delivering reliable and secure payment solutions, Convera enables users to navigate the complexities of cross-currency payments. In addition to its payment services, Convera also provides enterprise search and categorization solutions through its RetrievalWare technology, which allows organizations to efficiently access and manage vast amounts of unstructured information in multiple formats and languages. This dual focus on payments and information retrieval positions Convera as a valuable partner for organizations seeking to optimize their financial and data management processes.

Plazmic K.K. is a Japanese company that specializes in providing content deployment solutions for mobile devices globally. As a subsidiary of Research In Motion Limited, Plazmic offers a suite of software solutions designed to enable the creation and deployment of rich and dynamic content for wireless devices. The company focuses on delivering rich-media graphics that enhance user experience on mobile platforms. Founded by Jay Steele, who served as CTO and President, Plazmic had approximately 36 employees at the time of its acquisition, with teams located primarily in Toronto and Tokyo. The company's innovative approach attracted substantial investments prior to its acquisition, including support from notable venture capital firms.

Serveron Corporation specializes in developing and supporting online transformer products and diagnostic services. The company provides transformer monitors that deliver essential asset data, including dissolved gas analysis of insulating oil in power transformers and other oil-filled equipment. Its offerings also include monitoring services that allow users to access data from any internet-connected Windows PC, transformer bushing monitors for power factor testing, and advisory services to help utilities manage their transformer fleets. Additionally, Serveron focuses on energy asset management, enabling real-time monitoring, control, and reporting of remote energy systems. The company serves utilities, industrial users, and service organizations both in the United States and internationally. Headquartered in Hillsboro, Oregon, Serveron Corporation operates as a subsidiary of BPL Global, Ltd.

Nu-Wave Photonics is a manufacturer of optical sensors for detecting chemicals and biological agents.

Chancery Software is a leading provider of student information management solutions tailored for K-12 schools and districts. With over 15 years of industry experience, the company offers software tools designed to assist in the management of critical student information, including enrollments, scheduling, attendance, grading, and performance tracking. Chancery's solutions deliver accurate, real-time data on more than thirteen million students to one million educators daily, helping schools navigate the complexities of educational administration. The company has achieved over 18,000 installations across North America, customizing its offerings to meet the diverse needs and budgets of various educational institutions. Chancery Software is recognized as a trusted partner in the educational community, particularly in alignment with regulatory requirements such as the No Child Left Behind Act.

Knowledge Junction Systems develops and markets Business Intelligence and Smart e-Commerce Applications.

Prologic Corporation is the leading developer of software solutions for the global financial services industry. Their technologies enable financial institutions to quickly deploy solutions for their converging financial services offerings, while also supporting capabilities for increasing profitability, customer acquisition and retention. Through strategic alliances with Microsoft, Compaq Computer Corporation, EDS, Siemens Business Services, CAP Gemini, NRI, CGI, ISM-BC, APAK Systems and other international partners, Prologic’s financial solutions are in use in over 300 financial institutions globally. More than 20 Internet banks use Prologic solutions. 7 of the top 25 largest banks in the world use Prologic products.

Sedona Networks designs and builds innovative, multi-services access network solutions.